FENC
FENC clinical trials: FENNEC PHARMACEUTICALS INC.
Every trial on ClinicalTrials.gov where FENNEC PHARMACEUTICALS INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 12
- Trials linked
- 9
- As lead sponsor
- 3
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
FENC on the catalyst calendar · FENC registry changes
- Primary completion Aug 2012Sponsor estimatePhase 2NCT01231802Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast CancerAdherex Technologies, Inc. · Metastatic Breast CancerUnknown statusFENCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2009ActualPhase 1/Phase 2NCT00421811A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of MelphalanAdherex Technologies, Inc. · NeoplasmsCompletedFENCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 1NCT00390676A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or CapecitabineAdherex Technologies, Inc. · NeoplasmsCompletedFENCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 1/Phase 2NCT00265057Study of ADH-1 Given Intravenously to Patients With Solid TumorsAdherex Technologies, Inc. · NeoplasmsCompletedFENCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 1/Phase 2NCT00319683A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular CarcinomaAdherex Technologies, Inc. · Hepatocellular CarcinomaTerminatedFENCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2009Sponsor estimatePhase 1NCT00264472A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid TumorsAdherex Technologies, Inc. · NeoplasmsSuspendedFENCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 1NCT00264446A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic ResectionAdherex Technologies, Inc. · NeoplasmsCompletedFENCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 2NCT00264433A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single AgentAdherex Technologies, Inc. · NeoplasmsCompletedFENCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 1/Phase 2NCT00225550A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid TumorsAdherex Technologies, Inc. · NeoplasmsTerminatedFENCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2028Sponsor estimatePhase 1/Phase 2NCT07407582Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)University of Arizona · Solid Tumor MalignanciesRecruitingFENCCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2017ActualPhase 1NCT01825603ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract CancerUniversity of Nebraska · Ampulla of Vater AdenocarcinomaCompletedFENCCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT04132882A Compassionate Use Program to Provide Access to Sodium ThiosulfateTRPHARM · Cisplatin-Induced Hearing Loss in Children Who Had Standard-risk HepatoblastomaAvailableFENCCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 12 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner